vs
Side-by-side financial comparison of CYTOKINETICS INC (CYTK) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
ROCKWELL MEDICAL, INC. is the larger business by last-quarter revenue ($18.3M vs $17.8M, roughly 1.0× CYTOKINETICS INC). ROCKWELL MEDICAL, INC. runs the higher net margin — -3.0% vs -1030.9%, a 1027.9% gap on every dollar of revenue. On growth, CYTOKINETICS INC posted the faster year-over-year revenue change (4.9% vs -25.6%). ROCKWELL MEDICAL, INC. produced more free cash flow last quarter ($2.2M vs $-148.3M).
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
CYTK vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.8M | $18.3M |
| Net Profit | $-183.0M | $-554.0K |
| Gross Margin | — | 21.1% |
| Operating Margin | -1004.6% | -2.2% |
| Net Margin | -1030.9% | -3.0% |
| Revenue YoY | 4.9% | -25.6% |
| Net Profit YoY | -22.0% | 26.7% |
| EPS (diluted) | $-1.51 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.8M | $18.3M | ||
| Q3 25 | — | $15.9M | ||
| Q2 25 | $66.8M | $16.1M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | $16.9M | $24.7M | ||
| Q3 24 | — | $28.3M | ||
| Q2 24 | — | $25.8M | ||
| Q1 24 | — | $22.7M |
| Q4 25 | $-183.0M | $-554.0K | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | $-134.4M | $-1.5M | ||
| Q1 25 | — | $-1.5M | ||
| Q4 24 | $-150.0M | $-756.0K | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $343.0K | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 13.5% |
| Q4 25 | -1004.6% | -2.2% | ||
| Q3 25 | — | -9.9% | ||
| Q2 25 | -167.0% | -8.4% | ||
| Q1 25 | — | -7.2% | ||
| Q4 24 | -821.4% | -2.1% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | -5.8% |
| Q4 25 | -1030.9% | -3.0% | ||
| Q3 25 | — | -11.0% | ||
| Q2 25 | -201.2% | -9.3% | ||
| Q1 25 | — | -8.0% | ||
| Q4 24 | -886.3% | -3.1% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | -7.6% |
| Q4 25 | $-1.51 | $-0.01 | ||
| Q3 25 | — | $-0.05 | ||
| Q2 25 | $-1.12 | $-0.05 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | $-1.26 | $-0.02 | ||
| Q3 24 | — | $0.04 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $122.5M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-659.6M | $37.0M |
| Total Assets | $1.4B | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $122.5M | $10.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | $74.9M | $12.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | $94.9M | $15.7M | ||
| Q3 24 | — | $12.3M | ||
| Q2 24 | — | $11.9M | ||
| Q1 24 | — | $6.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $609.7M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $619.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-659.6M | $37.0M | ||
| Q3 25 | — | $37.0M | ||
| Q2 25 | $-368.7M | $30.4M | ||
| Q1 25 | — | $31.5M | ||
| Q4 24 | $-135.4M | $32.6M | ||
| Q3 24 | — | $29.1M | ||
| Q2 24 | — | $23.5M | ||
| Q1 24 | — | $20.6M |
| Q4 25 | $1.4B | $57.1M | ||
| Q3 25 | — | $57.5M | ||
| Q2 25 | $1.2B | $52.6M | ||
| Q1 25 | — | $54.0M | ||
| Q4 24 | $1.4B | $59.2M | ||
| Q3 24 | — | $57.1M | ||
| Q2 24 | — | $53.0M | ||
| Q1 24 | — | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-142.7M | $2.3M |
| Free Cash FlowOCF − Capex | $-148.3M | $2.2M |
| FCF MarginFCF / Revenue | -835.2% | 12.0% |
| Capex IntensityCapex / Revenue | 31.8% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-438.9M | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-142.7M | $2.3M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | $-128.2M | $1.8M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | $-65.6M | $865.0K | ||
| Q3 24 | — | $4.3M | ||
| Q2 24 | — | $1.4M | ||
| Q1 24 | — | $-2.4M |
| Q4 25 | $-148.3M | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | $-132.4M | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | $-66.9M | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | -835.2% | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | -198.3% | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | -395.0% | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% | ||
| Q1 24 | — | -11.1% |
| Q4 25 | 31.8% | 0.5% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | 6.2% | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | 7.6% | 1.6% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CYTK
| Other | $9.1M | 51% |
| Collaboration Revenues | $8.7M | 49% |
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
